Table 2 Ongoing clinical trials evaluating potential therapies in lung carcinoids
From: Systemic treatment for lung carcinoids: from bench to bedside
Molecular target | Study identifier | Study title | Study design | Population | Intervention | Primary endpoint |
|---|---|---|---|---|---|---|
Angiogenesis | NCT01841736 | – | Phase 2 RANDOMIZEDDOUBLE-blind | Advanced well differentiated NENs | Pazopanib vs PCB | PFS |
NCT00605566 | – | Phase 2 Single arm Open-label | Advanced well differentiated NENs | Sorafenib + metronomic cyclophosphamide | ORR | |
NCT02795858 | – | Phase 2 Single arm Open-label | Advanced extra-pancreatic well differentiated NENs | Ramucirumab + SSA | PFS | |
NCT01782443 | – | Phase 2 Single arm Open-label | Advanced well differentiated NENs | Ziv-aflibercept | PFS | |
NCT03375320 | CABINET | Phase 3 Randomized double-blind | Advanced well differentiated NENs | Cabozantinib vs PCB | PFS | |
NCT02588170 | – | Phase 3 Randomized double-blind | Advanced extra-pancreatic well differentiated NENs | Surufatinib vs PCB | PFS | |
NCT02259725 | – | Phase 2 Single arm Open-label | Advanced well differentiated NENs | Regorafenib | PFS | |
NCT01744249 | – | Phase 2–3 Randomized double-blind | Advanced extra-pancreatic well differentiated NENs | Axitinib + Octreotide LAR vs PCB + Octreotide LAR | PFS | |
NCT02399215 | – | Phase 2 Single arm Open-label | Advanced extra-pancreatic well differentiated NENs | Nintedanib | PFS | |
ErbB | NCT00843531 | – | Phase 2 | Moderately to well differentiated advanced NENs | Everolimus + Erlotinib | ORR |
ALK | NCT02568267 | STARTRK-2 | Phase 2 Basket study | Solid tumors (including NENs) harboring NTRK 1/2/3, ROS1 or ALK rearrangement | Entrectinib | ORR |
CDK 4/6 | NCT02420691 | – | Phase 2 Single arm Open-label | Foregut advanced well differentiated NENs | Ribociclib | ORR |
NCT03070301 | – | Phase 2 Single arm Open-label | Foregut advanced well differentiated NENs | Ribociclib + Everolimus | PFS | |
Immuno-therapy | NCT02955069 | – | Phase 2 Single arm Open-label | Advanced well differentiated NENs of pancreatic, GI or thoracic origin and advanced GEP-NECs | PDR-001 | ORR |
NCT03278379 | NET-002 | Phase 2 Single arm Open-label | Advanced well differentiated NENs | Avelumab | ORR | |
NCT03420521 | – | Phase 2 Single arm Open-label | Advanced well differentiated NENs of pancreatic, GI or lung origin (3 cohorts) | Nivolumab + Ipilimumab | ORR | |
NCT02923934 | – | Phase 2 Single arm Open-label | Rare cancers (including NENs) | Nivolumab + Ipilimumab | CBR | |
NCT03095274 | DUNE | Phase 2 Single arm Open-label | Advanced well differentiated NENs of pancreatic, GI or lung origin and advanced GEP-NECs (4 cohorts) | Durvalumab + Tremelimumab | CBR | |
NCT03728361 | – | Phase 2 Single arm Open-label | Progressive SCLC and advanced NENs (2 cohorts) | Nivolumab + Temozolomide | ORR |